Thursday, August 23, 2012

After almost 20 years of needle jabs

What are we to make of a large study concluding that interferon-beta did not affect the progress of MS patients' disability? Was Betaseron/Avonex/Rebif just making our MRIs look nicer? The jury's still out (compare this recent study on the cost effectiveness of interferon-beta), but at the tail end of a brutal summer, the news felt like a gut punch.

No comments: